The Vision Behind Artemis
The Partnership behind Artemis and UBC – Where time, place, and minds align.
Rooted in a heritage of learning and scientific rigor, and through our partnership with the University of British Columbia, Artemis honours the long arc of discovery — knowing that timing matters as much as insight.
Symbolic of the iconic clock tower anchoring campus mindshare and connection, and subtly shaped by West Coast imagery, Artemis wanted to convey balance, perspective, and quiet confidence to bold ideas, grounded in nature and open horizons.
At our centre is collaboration: different minds leaning into one shared mission, where trust, curiosity, and collective intelligence turn questions into progress.
This is discovery born of place, guided by legacy, and advanced together.
About Artemis Therapeutics
Artemis Therapeutics was founded by Dr. Artem Cherkasov and Dr. Mads Daugaard to harness more than three decades of pioneering research in molecular modelling, machine learning, and functional drug validation. Built at the intersection of computational science and translational medicine, Artemis brings together deep technical expertise and real-world therapeutic ambition.
At the core of Artemis is a proprietary AI-driven discovery platform designed to accelerate the identification of safe and effective drug candidates. By integrating advanced computational methods with rigorous biological validation, the platform increases both the speed and precision of early-stage drug discovery — transforming vast molecular data into actionable insight.
This is not theoretical innovation. The Artemis platform has already demonstrated its strength as a proven discovery engine, with six drug candidates identified using the technology having been licensed to pharmaceutical partners. Underpinning this success is a track record of scientific excellence, including two international drug discovery competition wins by Dr. Cherkasov using the foundational technologies behind Artemis.
Artemis is structured as an asset-driven biopharma company. We build and advance our own therapeutic assets, enabling us to capture the full value of innovation while maintaining strategic focus and scientific integrity.
Our leadership team and Scientific Advisory Board include globally recognized pioneers in AI-enabled drug discovery, computational chemistry, oncology, and translational medicine. Together, they bring the experience required to bridge visionary science with disciplined execution.
Let’s Advance Discovery Together
If you are interested in partnering, investing, or exploring scientific collaboration, we welcome the conversation.